In a breakthrough that could reshape the future of organ shortage, a genetically engineered pig kidney functioned inside a 66‑year‑old patient for 271 days – the longest clinical xenotransplant on record. The result, reported by BBC World on 3 September 2026 and based on a Lancet paper, shows that heavily edited pig kidneys can serve as a temporary bridge until a human donor organ becomes available.
Record‑breaking duration
The transplant was performed on 25 January 2025 at Mass General Brigham in Boston, United States. Tim Andrews, 66, received the pig kidney and the organ continued to work for 271 days before it was removed on 2 October 2025. The BBC World article states, "A kidney transplanted from a pig has worked inside a patient for 271 days – the longest on record, say US doctors." The same source adds that the kidney "worked immediately" and that the team’s data were published in the Lancet medical journal.
"A kidney transplanted from a pig has worked inside a patient for 271 days – the longest on record, say US doctors." – BBC World, 3 Sept 2026
After removal, Andrews spent a short period on dialysis before receiving a human donor kidney around 15 October 2025, according to the timeline supplied in the research packet.
Why a "bridge" matters
Kidney failure patients often spend years on waiting lists for a suitable human donor. During that time they must undergo regular dialysis, a process that can be physically taxing and costly. The Mass General Brigham team describes the pig organ as a "bridge" – a temporary solution that can keep patients out of dialysis while they await a human kidney.
"The team at Mass General Brigham hospital say their work shows pig organs can be used as a 'bridge' until a human transplant becomes available." – BBC World, 3 Sept 2026
By providing a functioning kidney for most of a nine‑month period, the xenograft spared Andrews months of hospital visits for dialysis. In his own words, the transplant gave him "hope" and reduced the need for frequent trips to have his blood filtered.
"Tim Andrews said the transplant gave him 'hope' and spared him months of needing to go to hospital to have his blood filtered by a dialysis machine." – BBC World, 3 Sept 2026
While the organ eventually failed – a known risk with early‑stage xenotransplantation – the duration of function demonstrates that genetically edited pig kidneys can sustain human physiology for a clinically meaningful period.
The team, the timeline and the institution
Mass General Brigham, a Boston‑based health system founded in 1994, led the procedure. The packet does not list a chief executive or employee count, noting that the Wikidata entry may be out‑of‑date. Nonetheless, the institution’s reputation in transplant research adds weight to the findings.
| Date | Event |
|---|---|
| 25 January 2025 | Tim Andrews receives genetically engineered pig kidney at Mass General Brigham. |
| 2 October 2025 | Pig kidney removed after 271 days of function; patient placed on short‑term dialysis. |
| ≈ 15 October 2025 | Patient receives a human donor kidney transplant. |
| 3 September 2026 | BBC World reports the 271‑day result, citing the Lancet paper. |
Source: BBC World (3 Sept 2026)
The timeline underscores that the xenograft provided a bridge of roughly nine months – a period that could be decisive for many patients whose waiting times exceed a year.
Implications for the kidney‑donor shortage
Canada’s own kidney‑waiting list mirrors the situation in the United States: thousands of patients await a donor organ, and many spend years on dialysis. If pig kidneys can reliably function for several months, they could reduce the time patients spend on dialysis, lower healthcare costs, and improve quality of life.
However, the packet makes clear that the pig organ eventually failed and required removal. The team’s statement that the result "shows pig organs can be used as a bridge" is cautious, not a claim that pig kidneys will replace human donors outright. The research is still at an early clinical stage, and broader adoption will depend on further trials, regulatory approval, and public acceptance.
What remains unknown
- Long‑term safety: The packet does not provide data on immune reactions beyond the 271‑day period.
- Scalability: No information is given about how many pig kidneys could be produced for a national programme.
- Cost: The research packet contains no figures on the expense of producing a genetically edited pig kidney versus a human transplant or dialysis.
- Regulatory pathway: Neither the Lancet paper nor the BBC coverage detail the steps required for approval in Canada or elsewhere.
These gaps mean that while the case is a promising proof‑of‑concept, policymakers and clinicians will need more data before integrating xenotransplantation into standard kidney‑failure treatment pathways.
Looking ahead
The 271‑day record sets a new benchmark for xenotransplant research. It provides a concrete example that a pig kidney can sustain human life for a period long enough to act as a bridge. For patients on Canada’s waiting list, the prospect of a temporary, biologically active organ could eventually translate into fewer months on dialysis and a better chance of a successful human transplant.
Future studies will need to confirm whether the bridge effect can be replicated across a broader patient population, determine the optimal genetic edits to minimise rejection, and address the ethical and logistical questions that arise when animal organs are used in humans.
Until then, the story of Tim Andrews offers a glimpse of a possible future where the shortage of donor kidneys is eased not by more human donors, but by a new class of engineered animal organs.